Trial Profile
To assess safety, Pharmacokinetics and antiviral activity of AT-527 in cirrhotic HCV-infected subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Bemnifosbuvir (Primary)
- Indications Liver cirrhosis
- Focus Pharmacokinetics
- 07 Dec 2018 New trial record
- 13 Nov 2018 Results presented at The Liver Meeting 2018: 69th Annual Meeting of the American Association for the Study of Liver Diseases